Young Research & Publishing Inc.

Investment Research Since 1978

Disclosure

  • About Us
    • Contributors
    • Archives
    • Dick Young’s Safe America
    • The Final Richard C. Young’s Intelligence Report
    • You’ve Read The Last Issue of Intelligence Report, Now What?
    • Dick Young’s Research Key: Anecdotal Evidence Gathering
    • Crisis at Vanguard
  • Investment Analysis
    • Bonds
    • Currencies and Gold
    • Dividend Investing
    • ETFs & Funds
    • Investment Strategy
    • Retirement Investing
    • Stocks
    • The Efficient Frontier
  • Investment Counsel
  • Dynamic Maximizers®
  • Retirement Compounders®
  • Free Email Signup

Novartis Leads from the Front on Cancer Treatment

November 19, 2018 By Jeremy Jones, CFA

By Crystal Eye Studio @ Shutterstock.com

Novartis is working on pioneering advanced new cancer therapies, rather than looking for incremental improvements in existing drugs. Denise Roland explains Novartis’ strategy at The Wall Street Journal, writing:

Novartis AG’s NVS +0.43% recent acquisition streak is pivoting the company toward new treatments that bear little resemblance to traditional drugs.

The Swiss company has spent nearly $15 billion in the past year to build its presence in cutting-edge areas of medical research, including gene therapy, or treatments that introduce new DNA into the body, and radiopharmaceuticals, which are drugs that carry radioactive particles to tumors for close-range radiotherapy.

The deals build on Novartis’s early move into a new form of cancer therapy known as CAR-T, and underscore new Chief Executive Vas Narasimhan’s ambition to get ahead on innovative therapies that he believes will drive significant future growth.

“We thought if we could gain a leadership position it’d be harder for competition to take us on,” Dr. Narasimhan, who led drug development at Novartis before becoming CEO, said in an interview. The 42-year-old Harvard-trained doctor said at a recent investor event that he hopes such therapies will generate a fifth of Novartis’s revenue within five years. Currently, they are a tiny fraction of its $49 billion in yearly sales.

The new treatments pose challenges. The jury is still out on how gene therapies, which potentially offer one-time cures for previously untreatable diseases, should be priced. Radiopharmaceuticals are logistically challenging to deliver because of the short half-life of the radioactive component.

Dr. Narasimhan acknowledged at the event that risks were higher than with conventional drugs but added that “there’s a risk in not pushing into new technologies and new areas of science to find breakthrough medicines.”

Read more here.

Radiopharmaceuticals – a key component of nuclear medicine

Share this:

  • Email
  • Twitter
  • Facebook

You Might Also Like:

  • Why Does Healthcare in America Cost so Much?
  • Hospitals Take a Step Back from Amazon’s Healthcare Push
  • Healthcare Could Cost You Your Retirement
  • Author
  • Recent Posts
Jeremy Jones, CFA
Jeremy Jones, CFA, CFP® is the Director of Research at Young Research & Publishing Inc., and the Chief Investment Officer at Richard C. Young & Co., Ltd. Richard C. Young & Co., Ltd. was ranked #5 in CNBC's 2021 Financial Advisor Top 100. Jeremy is also a contributing editor of youngresearch.com.
Latest posts by Jeremy Jones, CFA (see all)
  • Despite Inflation, Best Year Ever for Vacation Demand - July 1, 2022
  • Purchases of Gaming Chips for Crypto Mining Tailing Off - June 30, 2022
  • Are Google, Amazon, and Microsoft About to Crash This Specialized Real Estate Market? - June 29, 2022

Search Young Research

Most Popular

  • Here’s Why You Need a 15-Year Retirement Investment Plan
  • Why Work When Taxes Take It All?
  • Are Google, Amazon, and Microsoft About to Crash This Specialized Real Estate Market?
  • What Happens to Your Passwords When You Die?
  • Is the Great Job Boom Over?
  • Regulators' Bungled Attempts to Cut Emissions Drove Oil Prices Higher
  • RURAL RENAISSANCE: America Finds the Country Again
  • Your Survival Guy: Clearing the Decks, Buying a Boat, Seeing the World and More
  • Vanguard Wellesley (VWINX) vs. Wellington (VWELX): Which Fund is Best?
  • The Power of a Compound Interest Table

Don’t Miss

Default Risk Among the Many Concerns with Annuities

Risk and Reward: An Efficient Frontier

How to be a Billionaire: Proven Strategies from the Titans of Wealth

Could this Be the Vanguard GNMA Winning Edge?

Cryptocosm and Life After Google

Warning: Avoid Mutual Fund Year End Distributions

Is Gold a Good Long-term Investment?

How to Invest in Gold

Vanguard Wellington (VWELX): The Original Balanced Fund

What is the Best Gold ETF for Investing and Trading?

Procter & Gamble (PG) Stock: The Only True Dividend King

The Dividend King of the North

You’ll Love This if You’re Dreaming of an Active Retirement Life

RSS The Latest at Richardcyoung.com

  • Happy Independence Day
  • For Investors Who Want to Stop Worrying About a Market Crash
  • Breaking News: House Election Update
  • WATCH: New York Governor Melts Down When Asked for Facts
  • Florida Is a Refresher Course in American Greatness
  • Should You Believe Ms. Hutchinson?
  • Biden’s Economy Even Weaker than Thought
  • A Cashless Society Is A Debacle for Americans
  • Time to Save, Troubles Dining Out, and Intelligence on Yellowstone
  • Democrats Running AWAY from Biden on the Campaign Trail

About Us

  • About Young Research
  • Archives
  • Contributors

Our Partners

  • Richard C. Young & Co.
  • Richardcyoung.com

Copyright © 2022 | Terms & Conditions

 

Loading Comments...
 

    loading Cancel
    Post was not sent - check your email addresses!
    Email check failed, please try again
    Sorry, your blog cannot share posts by email.